{
  "num_tested_probands": [
    [
      3
    ],
    [
      6
    ],
    [
      32
    ]
  ],
  "num_positive_het_probands": [
    [
      1
    ],
    [
      2
    ],
    [
      10
    ]
  ],
  "positive_phenotypes": [
    [
      "heterozygous for the atypical variant and a silent variant",
      "homozygous for silent variants",
      "heterozygous for the atypical variant"
    ],
    [
      "prolonged duration of action of succinylcholine",
      "heterozygous for BCHE*FS126"
    ],
    [
      "AARS2",
      "CSF1R-negative patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia",
      "mivacurium in patients with phenotypically abnormal plasma cholinesterase activity",
      "H-variant segregating in two Danish families",
      "dibucaine numbers",
      "fluoride: recognition of two new phenotypes",
      "inhibition of serum cholinesterase by urea",
      "pseudocholinesterase variant in human tissues",
      "response to mivacurium in a patient compound heterozygous for a novel and a known silent mutation in the butyrylcholinesterase gene-Genotyping by sequencing",
      "unstable variant (BChE115D) of human butyrylcholinesterase"
    ]
  ],
  "num_compound_or_double_hets": [
    [
      0
    ],
    [
      1
    ],
    [
      2
    ]
  ],
  "explanation": {
    "num_tested_probands": [
      [
        "The probands were referred to DCRU because of prolonged duration of action of succinylcholine."
      ],
      [
        "The proband in family 1 had the genotype BCHE*115D*I3E4-14C/BCHE*FS126 and displayed prolonged duration of action of succinylcholine."
      ],
      [
        "The number of probands tested is 32."
      ]
    ],
    "num_positive_het_probands": [
      [
        "One proband was heterozygous for a silent variant and another was homozygous for silent variants."
      ],
      [
        "One patient with a low BChE activity was genotyped as heterozygous for BCHE*FS126 (Table 1, patient 2\u20133)."
      ],
      [
        "The number of probands who were heterozygous for a pathogenic variant is 10."
      ]
    ],
    "positive_phenotypes": [
      [
        "The phenotypes found in the study were AS, SS, and US."
      ],
      [
        "The proband in family 3 had a prolonged duration of action of succinylcholine of 90 min."
      ],
      [
        "Clinical phenotypes associated with the positive probands include AARS2, CSF1R-negative patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, mivacurium in patients with phenotypically abnormal plasma cholinesterase activity, H-variant segregating in two Danish families, dibucaine numbers, fluoride: recognition of two new phenotypes, inhibition of serum cholinesterase by urea, pseudocholinesterase variant in human tissues, response to mivacurium in a patient compound heterozygous for a novel and a known silent mutation in the butyrylcholinesterase gene-Genotyping by sequencing, unstable variant (BChE115D) of human butyrylcholinesterase."
      ]
    ],
    "num_compound_or_double_hets": [
      [
        "No compound or double heterozygotes were reported."
      ],
      [
        "Patient 3 was compound heterozygous for BCHE*328D and BCHE*142M."
      ],
      [
        "The number of individuals reported to have compound or double heterozygous mutations is 2."
      ]
    ]
  },
  "quote_snippets": [
    [
      "mutations in BCHE result in an extensively prolonged duration of action of succinylcholine",
      "BCHE*FS126 results in a truncated protein lacking the active site and is therefore inactive",
      "BCHE*328D also results in an inactive protein, as this change in amino acid is radical and further situated in the gorge harbouring the active site"
    ],
    [
      "mutations in AARS2 in a series of CSF1R-negative patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.",
      "prolonged duration of action of succinylcholine after mivacurium-induced neuromuscular blockade in phenotypically normal patients.",
      "prolonged paralysis after mivacurium in a patient apparently heterozygous for the atypical and usual pseudocholinesterase alleles by conventional biochemical testing.",
      "prolonged mivacurium neuromuscular block in children.",
      "sensitivity of butyrylcholinesterase knockout mice to (\u2013)huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer\u2019s disease drugs and indicates butyrylcholinesterase function in neurotransmission.",
      "identification of human plasma cholinesterase variants in 6688 individuals using biochemical analysis."
    ],
    [
      "mutations in AARS2 in a series of CSF1R-negative patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.",
      "mutations in AARS2 in a series of CSF1R-negative patients with adult-onset leu-",
      "koencephalopathy with axonal spheroids and pigmented glia.",
      "dibucaine numbers",
      "fluoride: recognition of two new phenotypes",
      "inhibition of serum cholinesterase by urea. Mechanism of action and application in the typing of abnormal genes.",
      "The inhibition of serum cholinesterase by urea.",
      "A pseudocholinesterase variant in human tissues.",
      "response to mivacurium in a patient compound heterozygous for a novel and a known silent mutation in the butyrylcholinesterase gene-Genotyping by sequencing.",
      "Characterization of an unstable variant (BChE115D) of human butyrylcholinesterase.",
      "Characterization of 12 silent alleles of the human butyrylcholinesterase (BCHE) gene."
    ]
  ]
}